Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12620000056998
ACTRN12620000056998
Not Yet Recruiting
N/A

A multi-centre, multi-specialty collaboration for creating a consistent valid scoring tool using patient skin field photographs for tumour severity and extent assessment of skin field cancerisation

GenesisCare0 sites150 target enrollmentJanuary 23, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSkin Cancer including Keratinocyte CarcinomasSkin - Dermatological conditionsCancer - Malignant melanomaCancer - Non melanoma skin cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Skin Cancer including Keratinocyte Carcinomas
Sponsor
GenesisCare
Enrollment
150
Status
Not Yet Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 23, 2020
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Treatable region of Skin Field Cancerisation in at least one of the following regional areas:
  • •o Cheek (one)
  • •o Ear (one)
  • •o Forearm (one)
  • •o Back of Hand (one)
  • •o Lower leg (one)
  • •o Top of foot (one)
  • •o Chest (Decolletage)
  • •o Torso (or front or back)
  • •2\. De\-identified \- Photographs of participants over 18 years of age. Photographs will be collected only from two sites from patients who attended clinics .These two sites are QIDerm in Brisbane and St Vincent's Hospital in Melbourne.

Exclusion Criteria

  • •Poor quality photographs;
  • •Other dermatoses effecting assessment (e.g. inflammatory
  • •skin diseases) that may confuse scorers.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
Phase 1
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2022-001837-35-LTBasilea Pharmaceutica International Ltd, Allschwil15
Active, Not Recruiting
Phase 1
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2022-001837-35-PLBasilea Pharmaceutica International Ltd, Allschwil15
Active, Not Recruiting
Phase 1
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2022-001837-35-SKBasilea Pharmaceutica International Ltd, Allschwil8
Active, Not Recruiting
Phase 1
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of age
EUCTR2022-001837-35-DEBasilea Pharmaceutica International Ltd, Allschwil8
Active, Not Recruiting
Phase 1
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of age
EUCTR2022-001837-35-BGBasilea Pharmaceutica International Ltd, Allschwil8